J Korean Neurosurg Soc.  2015 Jun;57(6):390-395. 10.3340/jkns.2015.57.6.390.

Epidemiology of Moyamoya Disease in Korea: Based on National Health Insurance Service Data

• Kim T
• Lee H
• Bang JS
• Kwon OK
• Hwang G
• Oh CW

• KMID: 2191243
• DOI: http://doi.org/10.3340/jkns.2015.57.6.390

Abstract

There have been a few studies reporting the epidemiology of moyamoya disease in Korea. Previous studies revealed relatively high prevalence and incidence of moyamoya disease in Korea and Japan. This study was designed to provide the latest epidemiologic information of moyamoya disease in Korea. We analyzed a database comprising of 50 million people covered in Korea by the National Health Insurance Service to calculate the prevalence. The incidence was estimated by eliminating the duplicated records of previous 3 years. We summarized the prevalence and incidence according to age, sex, and local distribution. In addition, the chronological changes were demonstrated with direct standardization using the 2010 population structure information. The standardized prevalence was 6.5 per 100000 persons in 2005, which was increased to 18.1 in 2013. In the same period, standardized incidence was increased from 2.7 to 4.3 per 100000 persons. The prevalence for men was 4.9 and 8.3 for women in 2005. In 2013, the prevalence had increased for men and women to 13.8 and 25.3, respectively. The incidence for men and women was 2.2 and 3.2, respectively, in 2005. It had increased to 3.5 and 5.7, respectively. The mean age of patients was 33.5 in 2005 and increased to 42.5 in 2013. The peak prevalent age group had shifted slightly to the older age groups, with chronologically consistent female predominance. The prevalence was highest in Jeollabuk province and lowest in Ulsan city.

Keyword

Epidemiology; Korea; Moyamoya disease

MeSH Terms

Epidemiology*
Female
Humans
Incidence
Japan
Korea
Male
Moyamoya Disease*
National Health Programs*
Prevalence
Ulsan

Figure

• 

  Fig. 1 The prevalence and incidence of moyamoya disease in Korea from 2005 to 2013.

• 

  Fig. 2 The prevalence of moyamoya disease by age and sex in 2005 and 2013. The prevalence of moyamoya disease increased during this period. The largest increment of patients was seen in middle aged women.

• 

  Fig. 3 The incidence of moyamoya disease by age and sex. In populations over 40 years old, the incidence change was prominent in women than in men. In 2013, the peak incidence was shown in ages 10-19 and 50-59.

• 

  Fig. 4 The local distribution of prevalence and incidence of moyamoya disease. Jeollabuk was the province with highest prevalence and incidence in 2013.

Reference

1. Ahn IM, Park DH, Hann HJ, Kim KH, Kim HJ, Ahn HS. Incidence, prevalence, and survival of moyamoya disease in Korea : a nationwide, population-based study. Stroke. 2014; 45:1090–1095. PMID: 24595588.

2. Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry. 2008; 79:900–904. PMID: 18077479.

3. Chen PC, Yang SH, Chien KL, Tsai IJ, Kuo MF. Epidemiology of moyamoya disease in Taiwan : a nationwide population-based study. Stroke. 2014; 45:1258–1263. PMID: 24676775.

4. Choi KS. Moyamoya disease in Korea. In : Suzuki J, editor. Advances in Surgery for Cerebral Stroke. Tokyo: Springer-Verlag;1988. p. 107–109.

5. Hung CC, Tu YK, Su CF, Lin LS, Shih CJ. Epidemiological study of moyamoya disease in Taiwan. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S23–S25. PMID: 9409399.

6. Ikezaki K, Han DH, Kawano T, Inamura T, Fukui M. Epidemiological survey of moyamoya disease in Korea. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S6–S10. PMID: 9409396.

7. Im SH, Cho CB, Joo WI, Chough CK, Park HK, Lee KJ, et al. Prevalence and epidemiological features of moyamoya disease in Korea. J Cerebrovasc Endovasc Neurosurg. 2012; 14:75–78. PMID: 23210031.

8. Kleinloog R, Regli L, Rinkel GJ, Klijn CJ. Regional differences in incidence and patient characteristics of moyamoya disease : a systematic review. J Neurol Neurosurg Psychiatry. 2012; 83:531–536. PMID: 22378916.

9. Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S, et al. Prevalence and clinicoepidemiological features of moyamoya disease in Japan : findings from a nationwide epidemiological survey. Stroke. 2008; 39:42–47. PMID: 18048855.

10. Kuroda S, Houkin K. Moyamoya disease : current concepts and future perspectives. Lancet Neurol. 2008; 7:1056–1066. PMID: 18940695.

11. Liu W, Hitomi T, Kobayashi H, Harada KH, Koizumi A. Distribution of moyamoya disease susceptibility polymorphism p.R4810K in RNF213 in East and Southeast Asian populations. Neurol Med Chir (Tokyo). 2012; 52:299–303. PMID: 22688066.

12. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011; 6:e22542. PMID: 21799892.

13. Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, et al. Epidemiological and clinical features of Moyamoya disease in Nanjing, China. Clin Neurol Neurosurg. 2010; 112:199–203. PMID: 20004511.

14. Miyamoto S, Yoshimoto T, Hashimoto N, Okada Y, Tsuji I, Tominaga T, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke. 2014; 45:1415–1421. PMID: 24668203.

15. Nam DH, Oh CW, Wang KC, Paek SH, Hwang YS, Kim IO, et al. Moyamoya disease : the differences between age groups in clinical presentation and hemodynamic characteristics. J Korean Neurosurg Soc. 1997; 26:1357–1362.

16. Natori Y, Ikezaki K, Matsushima T, Fukui M. 'Angiographic moyamoya' its definition, classification, and therapy. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S168–S172. PMID: 9409430.

17. Saeki N, Nakazaki S, Kubota M, Yamaura A, Hoshi S, Sunada S, et al. Hemorrhagic type moyamoya disease. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S196–S201. PMID: 9409437.

18. Suzuki J, Kodama N. Moyamoya disease--a review. Stroke. 1983; 14:104–109. PMID: 6823678.

19. Suzuki J, Takaku A. Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969; 20:288–299. PMID: 5775283.

20. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology. 2005; 65:956–958. PMID: 16186547.

21. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of moyamoya disease in Japan : findings from a nationwide survey. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S1–S5. PMID: 9409395.

22. Wetjen NM, Garell PC, Stence NV, Loftus CM. Moyamoya disease in the midwestern United States. Neurosurg Focus. 1998; 5:e1. PMID: 17112204.

23. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg. 1997; 99(Suppl 2):S58–S60. PMID: 9409407.